San Diego – March 29, 2022 – Each year, the San Diego Business Journal honors CFOs in the San Diego area who demonstrate resiliency, strategic vision, and above all, compelling financial growth. This year’s event was held in person at the Hyatt Regency La Jolla At Aventine in San Diego. DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that its Chief Financial Officer, Jill Howe has won the 2022 CFO of the Year Awards by the San Diego Business Journal.
“Jill is an exceptional leader, who has been instrumental in transforming the company’s financial infrastructure and positioned DTx Pharma opportunistically for its next fundraising milestone” said Arthur Suckow, CEO of DTx Pharma,
Jill’s leadership was recognized specifically for building and managing DTx Pharma’s financial team by hiring top-tier talent and laying the groundwork for the leading biotech. With the addition of a best-in-class controller among her hires since she joined the team, Jill has increased the staff at DTx Pharma by 6% in support of DTx Pharma’s growth.
The award also recognizes winners for philanthropic contributions, and as a San Diego native, Jill is heavily involved in her community. She is a volunteer with Promises2Kids where she helps bring kids together for fun activities and supports summer and recreational camp activities sponsored by the organization throughout the year.
“I am sincerely honored to be recognized by the San Diego Business Journal, especially for my role in shaping the company’s story around the market opportunity,” said Jill Howe. “I’m grateful to have an amazing team, they inspire me to work hard to contribute to the company’s efforts to develop its technology platform and bring therapeutics to patients who are searching for better treatment options.”
About DTx Pharma
DTx Pharma, Inc. is a private clinical-stage biotechnology company tackling the challenges associated with treating genetic conditions by leveraging RNA-based therapeutics. The company’s proprietary delivery technology platform utilizes fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body. In preclinical studies, DTx has demonstrated cellular uptake and broad activity of oligonucleotides in the retina, muscle, heart, neurons, T cells, and other specialized cell types. To advance the FALCON platform toward and into clinical development, DTx has raised more than $100M in combined investment from several of the world’s leading healthcare investors including RA Capital Management and Access Biotechnology, pharmaceutical companies such as Eli Lilly and Company, the National Institute of Health (NIH), and research foundations such as the CMT Research Foundation (CMTRF). To learn more about DTx Pharma, please visit www.dtxpharma.com and follow DTx on LinkedIn and Twitter @DTxPharma.